Bibliography
- Sakurai T, Amemiya A, Ishii M, Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
- Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52(4):891-903
- Chemelli RM, Willie JT, Sinton CM, Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437-51
- Beuckmann CT, Sinton CM, Williams SC, Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy–cataplexy in the rat. J Neurosci 2004;24(18):4469-77
- Lin L, Faraco J, Li R, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (Orexin) receptor 2 gene. Cell 1999;98(3):365-76
- Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8(11):977-87
- Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Patents 2010;20(3):307-24
- Christopher JA. Orexin receptor antagonists. Pharm Pat Analyst 2012;1(3):329-46
- Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Patents 2010;20(3):307-24
- Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010;5(8):1197-214
- Boss C, Brisbare-Roch C, Jenck F, Orexin receptor antagonism: a new principle in neuroscience. Chimia (Aarau) 2008;62(12):974-9
- Cox CD, Breslin MJ, Whitman DB, Discovery of the dual orexin receptor antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53(14):5320-32
- Winrow CJ, Gotter AL, Cox CD, Promotion of sleep by suvorexant – a novel dual orexin receptor antagonist. J Neurogenet 2011;25(1-2):52-61
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK4305 in Patients With Primary Insomnia – Study B. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01097629 [Last accessed 14 September 2012]
- Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia. Available from: www.merck.com/newsroom/news-release-archive/research-and-development/2012_0206.html [Last accessed 14 September 2012]
- Winrow CJ, Gotter AL, Cox CD, Pharmacological characterization of MK-6096 – a dual orexin receptor antagonist for insomnia. Neuropharmacology 2011;62(2):978-87
- Polysomnography Study of MK6096 in Patients With Primary Insomnia. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01021852 [Last accessed 14 September 2012]
- Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists. WO011775; 2009
- Actelion Pharmaceuticals Ltd. 1,2-Diamido-ethylene derivatives. WO022311; 2009